オキシコドン塩酸塩の世界市場 - 2025年～2033年

オキシコドン塩酸塩の世界市場は、2024年に4億1,000万米ドルに達し、2032年には5億300万米ドルに達すると予測され、予測期間2025年から2032年にはCAGR 9.0%で成長すると予測されています。

オキシコドン塩酸塩は強力なオピオイド鎮痛薬で、中等度から重度の疼痛管理に一般的に使用されます。脳と脊髄のオピオイド受容体に結合することで作用し、痛みに対する身体の知覚と情動反応を変化させる。オキシコドンは、即時放出錠剤、放出制御錠剤、内服液、他の薬との併用など、さまざまな製剤で入手可能です。これらの薬は経口、非経口、局所的に服用することができます。

市場力学：

促進要因と阻害要因

慢性疼痛疾患の有病率の増加

慢性疼痛疾患の有病率の増加は、世界のオキシコドン塩酸塩市場の重要な促進要因です。世界中の人口が高齢化するにつれて、関節炎、腰痛、糖尿病関連神経障害、線維筋痛症などの長期的な症状を抱える人が増えています。これらの慢性疼痛は、継続的な疼痛管理を必要とすることが多く、オキシコドン塩酸塩の安定した需要につながっています。例えば、米国疾病予防管理センターによると、2021年には米国成人の推定20.9％（5,160万人）が慢性疼痛を経験し、6.9％（1,710万人）が影響の大きい慢性疼痛を経験しています。

高齢者は慢性疼痛状態に陥りやすいため、世界人口の高齢化はこの問題をさらに悪化させています。このように、確実な疼痛緩和に対するニーズの高まりが、オキシコドン塩酸塩の普及を支え、慢性疼痛管理における重要な治療選択肢となっています。

オキシコドン塩酸塩に関連する合併症

オキシコドン塩酸塩に関連する副作用や健康リスクは、市場成長の大きな抑制要因となっています。オキシコドンは激しい疼痛管理に非常に有効であるが、潜在的なリスクもあります。便秘、吐き気、めまい、眠気などの一般的な副作用は患者のQOLに悪影響を及ぼし、治療不遵守につながる可能性があります。

さらに懸念されるのは、呼吸抑制、過量投与、長期依存（特に長期または慢性的な使用）のリスクです。このような健康上のリスクから、ヘルスケア提供者も患者も、特に長期の疼痛管理のための治療選択肢としてオキシコドンを検討する際には慎重になります。その結果、多くの人がより安全な代替薬を選ぶようになり、オキシコドンの広範な使用が制限され、市場の拡大が鈍化しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 慢性疼痛疾患の罹患率の増加
  • 抑制要因
    • オキシコドン塩酸塩に関連する合併症
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 タイプ別

• 制御放出
• 即時リリース

第7章 投与経路別

• 経口
• 非経口
• 局所

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Mallinckrodt Pharmaceuticals
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Lupin
• Taj Life Sciences Pvt. Ltd.
• Endo, Inc.
• Mylan Inc.
• DAIICHI SANKYO COMPANY, LIMITED
• Amneal Pharmaceuticals LLC.
• Pfizer Inc.
• Protega Pharmaceuticals Inc.

第12章 付録

第13章 問い合わせ

The global oxycodone hydrochloride market reached US$ 410 million in 2024 and is expected to reach US$ 503 million by 2032, growing at a CAGR of 9.0% during the forecast period 2025-2032.

Oxycodone hydrochloride is a potent opioid analgesic commonly used to manage moderate to severe pain. It works by binding to opioid receptors in the brain and spinal cord, altering the body's perception of pain and emotional response to it. Oxycodone is available in various formulations, including immediate-release and controlled-release tablets, oral solutions, and in combination with other medications. These medications can be taken orally, parenterally, and topically.

Market Dynamics: Drivers & Restraints

Increasing prevalence of chronic pain conditions

The increasing prevalence of chronic pain conditions is a significant driver for the global Oxycodone Hydrochloride market. As populations around the world age, more people are living with long-term conditions such as arthritis, back pain, diabetes-related neuropathy, and fibromyalgia. These chronic pain conditions often require ongoing pain management, leading to a consistent demand for Oxycodone Hydrochloride. For instance, according to the Centers for Disease Control and Prevention, in 2021 an estimated 20.9% of U.S. adults (51.6 million persons) experienced chronic pain, and 6.9% (17.1 million persons) experienced high-impact chronic pain.

The aging global population further exacerbates this issue, as older adults are more prone to chronic pain conditions. This growing need for reliable pain relief continues to support oxycodone hydrochloride's widespread use, making it a key treatment option in managing chronic pain.

Complications associated with oxycodone hydrochloride

The side effects and health risks associated with oxycodone hydrochloride serve as a significant restraint for its market growth. While oxycodone is highly effective in managing severe pain, it has potential risks. Common side effects such as constipation, nausea, dizziness, and drowsiness can negatively impact patient quality of life and lead to non-compliance with treatment.

More concerning are the risks of respiratory depression, overdose, and long-term dependence, especially with extended or chronic use. These health risks make both healthcare providers and patients cautious when considering oxycodone as a treatment option, particularly for long-term pain management. As a result, many opt for safer alternatives, limiting the widespread use of oxycodone and slowing its market expansion.

Segment Analysis

The global oxycodone hydrochloride market is segmented based on type, route of administration, distribution channel, and region

Type:

Controlled-release segment is expected to dominate the global oxycodone hydrochloride market share

The controlled-release segment of the oxycodone hydrochloride market is expected to dominate due to its ability to provide long-lasting pain relief, which is particularly beneficial for patients with chronic pain. Controlled-release formulations, such as OxyContin, release the drug gradually over an extended period, reducing the need for frequent dosing and helping to maintain consistent pain control throughout the day. This extended-release feature is especially important for managing chronic conditions like cancer, arthritis, and back pain, where constant pain relief is crucial.

The companies are manufacturing oxycodone hydrochloride tablets and medications with different formulations and are showing their effectiveness which are gaining approvals from the regulatory bodies.

Additionally, controlled-release formulations are often preferred because they are associated with a lower risk of abuse than immediate-release versions, as they are harder to misuse. As the demand for safer, more effective pain management options grows, the controlled-release segment is expected to remain a dominant force in the oxycodone hydrochloride market.

Geographical Analysis

North America is expected to hold a significant position in the global oxycodone hydrochloride market share

North America is expected to dominate the oxycodone hydrochloride market due to several key factors. The region, particularly the United States, has a high prevalence of chronic pain conditions, including back pain, arthritis, and cancer, which drives the demand for potent pain management options like oxycodone. For instance, in 2022, the age-adjusted prevalence of diagnosed arthritis in adults age 18 and older was 18.9%, with women (21.5%) more likely to have arthritis than men (16.1%).

Despite the growing concerns around opioid misuse and regulatory measures, oxycodone continues to be a commonly prescribed pain reliever in both acute and chronic pain cases. Furthermore, ongoing advancements in abuse-deterrent formulations and increased awareness of managing pain effectively contribute to the continued dominance of oxycodone in North America's pain management market. For instance, in October 2024, Protega Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for ROXYBOND (oxycodone hydrochloride) immediate-release (IR) CII 10 mg tablet for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ROXYBOND is the first and only FDA-approved abuse-deterrent IR 10 mg oxycodone formulation that is expected to reduce abuse by intranasal and intravenous routes.

Competitive Landscape

The major global players in the oxycodone hydrochloride market Mallinckrodt Pharmaceuticals, Lupin, Taj Life Sciences Pvt. Ltd., Endo, Inc., Mylan Inc., DAIICHI SANKYO COMPANY, LIMITED, Amneal Pharmaceuticals LLC., Pfizer Inc. and Protega Pharmaceuticals Inc. among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Oxycodone Hydrochloride Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of chronic pain conditions
  • 4.1.2. Restraints
    • 4.1.2.1. Complications associated with oxycodone hydrochloride
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Controlled-Release*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Immediate-Release

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Oral*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Parenteral
• 7.4. Topical

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Mallinckrodt Pharmaceuticals*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Lupin
• 11.3. Taj Life Sciences Pvt. Ltd.
• 11.4. Endo, Inc.
• 11.5. Mylan Inc.
• 11.6. DAIICHI SANKYO COMPANY, LIMITED
• 11.7. Amneal Pharmaceuticals LLC.
• 11.8. Pfizer Inc.
• 11.9. Protega Pharmaceuticals Inc.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services

13. Contact Us